172 related articles for article (PubMed ID: 25788547)
1. Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.
Nanfack AJ; Agyingi L; Noubiap JJ; Ngai JN; Colizzi V; Nyambi PN
J Clin Microbiol; 2015 May; 53(5):1662-71. PubMed ID: 25788547
[TBL] [Abstract][Full Text] [Related]
2. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
[TBL] [Abstract][Full Text] [Related]
3. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
4. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.
Zhou Z; Wagar N; DeVos JR; Rottinghaus E; Diallo K; Nguyen DB; Bassey O; Ugbena R; Wadonda-Kabondo N; McConnell MS; Zulu I; Chilima B; Nkengasong J; Yang C
PLoS One; 2011; 6(11):e28184. PubMed ID: 22132237
[TBL] [Abstract][Full Text] [Related]
7. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
[TBL] [Abstract][Full Text] [Related]
8. Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes.
Sacks D; Ledwaba J; Morris L; Hunt GM
J Clin Microbiol; 2017 Jan; 55(1):122-133. PubMed ID: 27795333
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay.
Kiertiburanakul S; Pinsai S; Chantratita W; Pasomsub E; Leechawengwongs M; Thipmontree W; Siriyakorn N; Sungkanuparph S
PLoS One; 2016; 11(2):e0147945. PubMed ID: 26828876
[TBL] [Abstract][Full Text] [Related]
10. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
[TBL] [Abstract][Full Text] [Related]
11. Development of a cost-effective assay for genotyping of HIV-1 non-B subtype for drug resistance.
Ammaranond P; Sanguansittianant S; Raju PA; Cunningham P; Horthongkham N
J Virol Methods; 2014 Apr; 199():102-7. PubMed ID: 24462843
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.
Aitken SC; Kliphuis A; Wallis CL; Chu ML; Fillekes Q; Barth R; Stevens W; Rinke de Wit TF; Schuurman R
J Clin Virol; 2012 May; 54(1):21-5. PubMed ID: 22306272
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania.
Fall-Malick FZ; Tchiakpé E; Ould Soufiane S; Diop-Ndiaye H; Mouhamedoune Baye A; Ould Horma Babana A; Touré Kane C; Lo B; Mboup S
J Med Virol; 2014 Mar; 86(3):404-10. PubMed ID: 24318486
[TBL] [Abstract][Full Text] [Related]
14. HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience.
Ngo-Malabo ET; Ngoupo PA; Sadeuh-Mba SA; Akongnwi E; Banaï R; Ngono L; Bilong-Bilong CF; Kfutwah A; Njouom R
Curr HIV Res; 2017; 15(4):297-305. PubMed ID: 28745207
[TBL] [Abstract][Full Text] [Related]
15. Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.
Fokam J; Takou D; Santoro MM; Akonie HZ; Kouanfack C; Ceccherini-Silberstein F; Colizzi V; Perno CF; Ndjolo A
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):329-33. PubMed ID: 26602836
[TBL] [Abstract][Full Text] [Related]
16. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Hunt GM; Morris L; Moorthy A; Coovadia A; Abrams EJ; Strehlau R; Kuhn L; Persaud D
J Virol Methods; 2014 Oct; 207():182-7. PubMed ID: 25034127
[TBL] [Abstract][Full Text] [Related]
17. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
18. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance.
Billong SC; Fokam J; Aghokeng AF; Milenge P; Kembou E; Abessouguie I; Meva'a-Onglene FB; Bissek AC; Colizzi V; Mpoudi EN; Elat JB; Shiro KS
PLoS One; 2013; 8(8):e72680. PubMed ID: 23991142
[TBL] [Abstract][Full Text] [Related]
19. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
Newman H; Breunig L; van Zyl G; Stich A; Preiser W
J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
[TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of Allele-Specific PCR (ASPCR) in detecting drug resistance mutations among non-B HIV-1 Variants.
Adawaye C; Fokam J; Kamangu EN; Ngwese DTA; Susin F; Moussa AM; Hig-Zounet B; Mad-Toingué J; Tidjani A; Vaira D; Moutschen M
J Virol Methods; 2024 Jan; 323():114856. PubMed ID: 38000668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
